Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

Inclusion Criteria:

- Subjects for whom the investigator believes their parents/guardians can and will
comply with the requirements of the protocol (e.g. completion of the diary cards,
return for follow-up visits) should be enrolled in the study.

- Male or female between 12 and 15 months of age (e.g. from age 12 months until the day
before age 16 months) at the time of vaccination.

- Written informed consent obtained from the parent/guardian of the subject.

- Healthy subjects as established by medical history and clinical examination before
entering into the study.

- Have previously received three doses of 7-valent pneumococcal conjugate vaccine within
the first year of life with the third dose administered at least 30 days prior to
enrolment and vaccination with study vaccines.

Exclusion Criteria:

- Use of any investigational or non-registered product (drug or vaccine) other than the
study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned
use during the study period.

- Concurrently participating in another clinical study, at any time during the study
period, in which the subject has been or will be exposed to an investigational or a
non-investigational product (pharmaceutical product or device).

- Chronic administration (defined as more than 14 days) of immunosuppressants or other
immune-modifying drugs within six months prior to the first vaccine dose.

- Planned administration/ administration of a vaccine not foreseen by the study protocol
from 30 days prior to vaccination until 42 days after vaccination, except for
influenza vaccine and Hib vaccine.

- Previous vaccination against measles, mumps, rubella and/or varicella.

- Previous vaccination against hepatitis A or receipt of a fourth dose of pneumococcal
conjugate vaccine.

- History of measles, mumps, rubella, varicella/zoster and hepatitis A diseases.

- Known exposure to measles, mumps, rubella and/or varicella/zoster within 30 days prior
to the start of the study.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
medical history and physical examination (no laboratory testing required), including
human immunodeficiency virus (HIV) infection.

- A family history of congenital or hereditary immunodeficiency.

- History of allergic disease or reactions likely to be exacerbated by any component of
the vaccines.

- Hypersensitivity to latex

- Major congenital defects or serious chronic illness.

- History of any neurologic disorders or seizures, including febrile seizures.

- Acute disease at the time of enrolment.

- Administration of polyclonal immunoglobulins and/or any blood products during the six
months before entering the study or planned administration during the study period.